OBJECTIVES/HYPOTHESIS: Head and neck squamous cell carcinoma (HNSCC) is a complex disease process involving interactions with carcinoma-associated fibroblasts and endothelial cells. We further investigated these relationships by suppressing stromal cell growth through the inhibition of fibroblast growth factor receptor (FGFR). STUDY DESIGN: Preclinical investigation. METHODS: HNSCC cell lines (FADU, OSC19, Cal27, SCC1, SCC5, SCC22A), fibroblast (HS27), and endothelial cells (human umbilical vascular endothelial cell) were cultured individually or in coculture. Proliferation was assessed following treatment with a range of physiologic concentrations of FGFR inhibitor PD173074. Mice bearing established HNSCC xenografts were treated with PD173074 (12 mg/kg), and tumor histology was analyzed for stromal composition, proliferation (Ki67 staining), and apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick end labeling] staining). RESULTS: In vitro, inhibition of FGFR with PD173074 dramatically reduced proliferation of fibroblasts and endothelial cells compared to untreated controls. However, HNSCC cell proliferation was not affected by inhibition of FGFR. When cocultured with fibroblasts, HNSCC cells proliferation increased by 15% to 80% (P < .01). Furthermore, this fibroblast-enhanced tumor cell growth was suppressed by FGFR inhibition. Additionally, treatment of mice bearing HNSCC xenografts with PD173074 resulted in significant growth inhibition (P < .001). Additionally, those tumors from mice treated with PD173074 had a smaller stromal component, decreased proliferation, and increased apoptosis. CONCLUSIONS: Targeting the FGFR pathway in head and neck cancer acts through the stromal components to decrease HNSCC growth in vivo and in vitro.
OBJECTIVES/HYPOTHESIS: Head and neck squamous cell carcinoma (HNSCC) is a complex disease process involving interactions with carcinoma-associated fibroblasts and endothelial cells. We further investigated these relationships by suppressing stromal cell growth through the inhibition of fibroblast growth factor receptor (FGFR). STUDY DESIGN: Preclinical investigation. METHODS: HNSCC cell lines (FADU, OSC19, Cal27, SCC1, SCC5, SCC22A), fibroblast (HS27), and endothelial cells (human umbilical vascular endothelial cell) were cultured individually or in coculture. Proliferation was assessed following treatment with a range of physiologic concentrations of FGFR inhibitor PD173074. Mice bearing established HNSCC xenografts were treated with PD173074 (12 mg/kg), and tumor histology was analyzed for stromal composition, proliferation (Ki67 staining), and apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick end labeling] staining). RESULTS: In vitro, inhibition of FGFR with PD173074 dramatically reduced proliferation of fibroblasts and endothelial cells compared to untreated controls. However, HNSCC cell proliferation was not affected by inhibition of FGFR. When cocultured with fibroblasts, HNSCC cells proliferation increased by 15% to 80% (P < .01). Furthermore, this fibroblast-enhanced tumor cell growth was suppressed by FGFR inhibition. Additionally, treatment of mice bearing HNSCC xenografts with PD173074 resulted in significant growth inhibition (P < .001). Additionally, those tumors from mice treated with PD173074 had a smaller stromal component, decreased proliferation, and increased apoptosis. CONCLUSIONS: Targeting the FGFR pathway in head and neck cancer acts through the stromal components to decrease HNSCC growth in vivo and in vitro.
Authors: Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal Journal: Mol Cancer Res Date: 2011-06-10 Impact factor: 5.852
Authors: Candice Wakulich; Linda Jackson-Boeters; Tom D Daley; George P Wysocki Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2002-05
Authors: Eben L Rosenthal; Satya Shreenivas; Glenn E Peters; William E Grizzle; Renee Desmond; Candece L Gladson Journal: Laryngoscope Date: 2003-08 Impact factor: 3.325
Authors: Choong-Kun Lee; Myung Eun Lee; Won Suk Lee; Jeong Min Kim; Kyu Hyun Park; Tae Soo Kim; Kang Young Lee; Joong Bae Ahn; Hyun Cheol Chung; Sun Young Rha Journal: Am J Cancer Res Date: 2014-12-15 Impact factor: 6.166
Authors: Tomasz Kolenda; Weronika Przybyła; Marta Kapałczyńska; Anna Teresiak; Maria Zajączkowska; Renata Bliźniak; Katarzyna M Lamperska Journal: Rep Pract Oncol Radiother Date: 2018-03-17
Authors: Dhruv Kumar; Jacob New; Vikalp Vishwakarma; Radhika Joshi; Jonathan Enders; Fangchen Lin; Sumana Dasari; Wade R Gutierrez; George Leef; Sivapriya Ponnurangam; Hemantkumar Chavan; Lydia Ganaden; Mackenzie M Thornton; Hongying Dai; Ossama Tawfik; Jeffrey Straub; Yelizaveta Shnayder; Kiran Kakarala; Terance Ted Tsue; Douglas A Girod; Bennett Van Houten; Shrikant Anant; Partha Krishnamurthy; Sufi Mary Thomas Journal: Cancer Res Date: 2018-05-16 Impact factor: 12.701
Authors: Molly E Heft Neal; Andrew C Birkeland; Apurva D Bhangale; Jingyi Zhai; Aditi Kulkarni; Susan K Foltin; Brittany M Jewell; Megan L Ludwig; Lisa Pinatti; Hui Jiang; Jonathan B McHugh; Lawence Marentette; Erin L McKean; J Chad Brenner Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430